ISSN: 0443-511
e-ISSN: 2448-5667
Usuario/a
Idioma
Herramientas del artículo
Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión)
Tamaño de fuente

Open Journal Systems

¿Síndrome de Vogt-Koyanagi-Harada crónico o sarcoidosis? Un diagnóstico sombrío / Recurrent chronic Vogt-Koyanagi-Harada syndrome or sarcoidosis? A Gloomy diagnosis

Juan José Gómez-Piña, Adriana Elizabeth Vázquez-Hernández, Nayeli Flores-Flores, Marco Antonio Cortés-Luis, Arturo Olvera-Acevedo

Resumen


Resumen

Introducción: el síndrome de Vogt-Koyanagi-Harada (VKH) es una enfermedad sistémica que afecta a órganos ricos en melanocitos y se manifiesta con una panuveítis granulomatosa bilateral, crónica y difusa, así como con manifestaciones neurológicas, auditivas y cutáneas. En este artículo se presenta un enfoque sistemático para el abordaje diagnóstico del síndrome de VKH y se consideran las posibilidades diagnósticas relevantes para descartar otras entidades que se presentan con síntomas similares.

Caso clínico: hombre de 71 años con antecedentes de vitiligo de larga data, quien experimentó una pérdida visual en su ojo derecho seis meses antes de su ingreso, junto con hipoacusia bilateral, predominantemente en el oído derecho. Durante su hospitalización, presentó cefalea crónica, fiebre y una significativa pérdida involuntaria de peso. En la exploración oftalmológica, el ojo derecho solo percibía luz y presentaba conjuntiva bulbar hiperémica, mientras que el ojo izquierdo tenía una agudeza visual de 20/200. El fondo del ojo derecho presentaba pigmentación dispersa, mientras que el izquierdo tenía una papila edematosa y atrofia óptica derecha.

Conclusiones: el diagnóstico del síndrome de VKH se establece mediante la presencia de los 5 criterios diagnósticos para la enfermedad completa, incluida la hipopigmentación retiniana, las alteraciones neurológicas y las manifestaciones dermatológicas. Dado que los pacientes pueden presentar una amplia variedad de síntomas, el diagnóstico diferencial debe considerarse inicialmente, lo que representa un desafío diagnóstico.

 

Abstract

Background: Vogt-Koyanagi-Harada syndrome (VKH) is a systemic disease that affects organs profuse in melanocytes, presenting with a chronic and diffuse bilateral granulomatous panuveitis, as well as neurological, auditory, and cutaneous manifestations. In this article, a systematic approach is presented for the diagnostic management of VKH syndrome, considering relevant diagnostic possibilities to rule out other entities that manifest similar symptoms.

Clinical case: 71-year-old man with a long-standing history of vitiligo, who experienced visual loss in his right eye 6 months before his admission, along with bilateral hearing loss predominantly in the right ear. During his hospitalization, he presented with chronic headache, fever, and significant involuntary weight loss. Ophthalmological examination revealed that his right eye only perceived light and had hyperemic bulbar conjunctiva, while the left eye had a visual acuity of 20/200. The right fundus had scattered pigmentation, while the left had an edematous optic disc and right optic atrophy.

Conclusions: The diagnosis of VKH syndrome is established by the presence of the 5 diagnostic criteria for complete disease, including retinal depigmentation, neurological alterations, and dermatological manifestations. Since patients can present with a wide variety of symptoms, initial differential diagnosis should be considered, which represents a diagnostic challenge.


Palabras clave


Síndrome de Vogt-Koyanagi-Harada; Síndrome Uveomeningoencefalítico; Uveomeningoencefalitis / Vogt-Koyanagi-Harada syndrome; Uveomeningoencephalitic Syndrome; Uveomeningoencephalitis

Texto completo:

PDF

Referencias


 

Sheu SJ. Update On Uveomeningoencephalitides. Curr Opin Neurol. 2005;18(3):323-9. doi: 10.1097/01.wco.0000169753.31321.4e.

Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada Syndrome. Surv Ophthalmol. 1995;39(4):265-92. doi: 10.1016/s0039-6257(05)80105-5.

AlBloushi AF, AlEnezi SH, Al Owaifeer AM, et al. Long-term Outcomes of Uveitis Associated with Vogt-Koyanagi-Harada Disease in the Pediatric Age Group. Ocul Immunol Inflamm. 2021:1-9. doi: 10.1080/09273948.2021.1933074.

Huang Y, Yang YT, Lin B, et al. Melanin Change Of Retinal Pigment Epithelium And Choroid In The Convalescent Stage Of Vogt-Koyanagi-Harada Disease. Int J Ophthalmol. 2020;13(12):1928-32. doi: 10.18240/ijo.2020.12.13.

Yang P, Zhong Y, Du L, et al. Development and Evaluation of Diagnostic Criteria for Vogt-Koyanagi-Harada Disease. JAMA Ophthalmol. 2018;136(9):1025-31. doi: 10.1001/jamaophthalmol.2018.2664.

Herbort CP Jr, Tugal-Tutkun I, Abu-El-Asrar A, et al. Precise, simplified diagnostic criteria and optimised management of initial-onset Vogt-Koyanagi-Harada disease: an updated review. Eye (Lond). 2022;36(1):29-43. doi: 10.1038/s41433-021-01573-3.

Sultan M, Khan A, Habib SS, et al. Unique clinical spectrum with distinguishing diagnostic features in Vogt-Koyanagi-Harada syndrome. BMJ Case Rep. 2019;12(12):1-6. doi: 10.1136/bcr-2019-231397.

Sakata VM, da Silva FT, Hirata CE, et al. High rate of clinical recurrence in patients with Vogt-Koyanagi-Harada disease treated with early high-dose corticosteroids. Graefes Arch Clin Exp Ophthalmol. 2015;253(5):785-90. doi: 10.1007/s00417-014-2904-z.

Rubsamen PE, Gass JD. Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome. Arch Ophthalmol. 1991;109(5):682-7. doi: 10.1001/archopht.1991.01080050096037.

Knecht PB, Mantovani A, Herbort CP. Indocyanine green angiography-guided management of Vogt-Koyanagi-Harada disease: differentiation between choroidal scars and active lesions. Int Ophthalmol. 2013;33(5):571-7. doi: 10.1007/s10792-012-9692-4.

Da Silva FT, Hirata CE, Sakata VM, et al. Indocyanine green angiography findings in patients with long-standing Vogt-Koyanagi-Harada disease: a cross-sectional study. BMC Ophthalmol. 2012;12:40. doi: 10.1186/1471-2415-12-40.

Herbort CP Jr, Mantovani A, Bouchenaki N. Indocyanine green angiography in Vogt-Koyanagi-Harada disease: angiographic signs and utility in patient follow-up. Int Ophthalmol. 2007;27(2-3):173-82. doi: 10.1007/s10792-007-9060-y.

Read RW, Yu F, Accorinti M, et al. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2006;142(1):119-24. doi: 10.1016/j.ajo.2006.02.049.

Lai TY, Chan RP, Chan CK, et al. Effects Of The Duration Of Initial Oral Corticosteroid Treatment On The Recurrence Of Inflammation In Vogt-Koyanagi-Harada Disease. Eye (Lond). 2009;23(3):543-8. doi: 10.1038/eye.2008.89.

Chee SP, Jap A, Bacsal K. Prognostic Factors Of Vogt-Koyanagi-Harada Disease In Singapore. Am J Ophthalmol. 2009;147(1):154-61.e1. doi: 10.1016/j.ajo.2008.07.044.

Kawaguchi T, Horie S, Bouchenaki N, et al. Suboptimal Therapy Controls Clinically Apparent Disease But Not Subclinical Progression Of Vogt-Koyanagi-Harada Disease. Int Ophthalmol. 2010;30(1):41-50. doi: 10.1007/s10792-008-9288-1.

Rao NA. Treatment Of Vogt-Koyanagi-Harada Disease By Corticosteroids And Immunosuppressive Agents. Ocul Immunol Inflamm. 2006;14(2):71-2. doi: 10.1080/09273940600674368.

Chee SP, Luu CD, Cheng CL, et al. Visual function in Vogt-Koyanagi-Harada patients. Graefes Arch Clin Exp Ophthalmol. 2005;243(8):785-90. doi: 10.1007/s00417-005-1156-3.

Tsai JH, Evans M, Rao NA. Comparative study of two sets of criteria for the diagnosis of Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2006;141(4):778-9. doi: 10.1016/j.ajo.2005.12.003.

Otani S, Sakurai T, Yamamoto K, et al. Frequent Immune Response To A Melanocyte Specific Protein KU-MEL-1 In Patients With Vogt-Koyanagi-Harada Disease. Br J Ophthalmol. 2006;90(6):773-7. doi: 10.1136/bjo.2005.086520.


Enlaces refback

  • No hay ningún enlace refback.